Latest Product Commercialisation News

Pathkey.AI has appointed Nanyang Technological University chip design and AI specialist Professor Anupam Chattopadhyay to the new Advisory Board supporting Chipforge. The appointment adds technical and commercialisation experience as the AI-native semiconductor platform moves from development towards a product launch, although no launch date or commercial contract was disclosed.

BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.

Integrated Research’s FY26 results reveal a sharp 91% drop in net profit amid softer renewals and rising expenses, offset by a 27% jump in cash and a special dividend. The company pushes forward with AI-powered products despite early-stage commercialisation risks.

Aureka Limited has reported new high-grade gold intercepts extending mineralisation southwards at its St Arnaud Comstock project, reinforcing plans for near-term production using nearby milling capacity.

Nanosonics reported steady FY26 revenue growth driven by its trophon disinfection platform and advanced the CORIS System towards commercial launch, backed by a strong balance sheet and a new $40 million share buyback.

BCAL Diagnostics has updated investors on its $10 million convertible note facility, revealing $7.6 million drawn to date with further funding contingent on upcoming shareholder approval.

Metallium Limited has demonstrated its Flash Joule Heating technology can process a broad range of critical metal feedstocks, from rare earth ores to industrial wastes, opening new commercial pathways beyond electronic waste.

Eden Innovations reported strong EdenCrete® trial results in India and North America, strategic hires for EdenShield® in defence markets, and completed a $4.05 million placement, ending the quarter debt-free with $5.2 million cash.

Lumos Diagnostics reported a 6% revenue increase to US$13.2 million for FY26, driven by an 875% surge in FebriDx® sales following a pivotal CLIA waiver. The company expanded U.S. adoption to 170+ healthcare sites and secured milestone payments exceeding US$6 million.

Papyrus Australia has tapped related party L39 Capital to lead a capital raise and secured an interest-bearing $200,000 loan from Irwin Biotech, with conversion into shares and options pending shareholder approval.

Wide Open Agriculture is closing its German plant and pivoting to contract manufacturing in Asia to cut costs and scale lupin ingredient production efficiently under new CEO Craig Swan.